Search reports, ask a question, or jump to a page.
The problem
Intervention: Measurement of serum AQP1 expression as a prognostic biomarker for treatment response and disease severity
Who it was tested with: 168 neonates with ABO hemolytic disease-related hyperbilirubinemia (84 high-AQP1, 84 low-AQP1); compared against a control group of unaffected neonates.
The same group is measured before the intervention and again afterwards, with a baseline and an endline and sometimes a midline. Change is visible, but other causes cannot be ruled out.
"A retrospective cohort study was conducted, enrolling 168 neonates with ABO-HDN-related hyperbilirubinemia. Serum AQP1 expression was detected by RT-qPCR, and neonates were divided into a high-AQP1 expression group (n = 84) and a low-AQP1 expression group (n = 84) according to the median." The biomarker successfully stratified neonates by treatment response severity, supporting its prognostic utility.
Retrospective design; country/setting not specified; follow-up limited to 7 days; no comparison of AQP1's predictive value against existing clinical assessment methods; potential selection bias in how neonates were enrolled.
Across countries and designs
1 study · 0 countries
Not yet reviewed by a person. Model output is not AICS's view until reviewed.
claude-haiku-4-5-20251001 · synth-v1
